Ovarian Cancer Reagents

Ovarian cancer is the most lethal gynecological malignancy, often diagnosed at advanced stages. Biomarker research — CA125/HE4 monitoring, BRCA-driven PARP inhibitor selection, and emerging ADC targets — is critical for improving outcomes. abinScience provides reagents for CA125/MUC16, HE4/WFDC2, BRCA, FOLR1, Mesothelin, and TROP2. RUO

Key Biomarkers & Targets

CA125 / MUC16

Cancer Antigen 125

The primary serum biomarker for ovarian cancer monitoring and recurrence detection. 30 antibodies and biosimilar proteins.

Antibodies • Biosimilars

HE4 / WFDC2

Human Epididymis Protein 4

Complementary biomarker to CA125; together they form the ROMA algorithm for ovarian mass risk stratification. 12 antibodies and proteins.

Antibodies • Proteins

FOLR1

Folate Receptor Alpha

Overexpressed in high-grade serous ovarian cancer; ADC target (mirvetuximab soravtansine). 29 antibodies and research-grade biosimilar proteins.

Antibodies • Biosimilars

Mesothelin

MSLN

Overexpressed in ovarian, mesothelioma, and pancreatic cancers. Target for CAR-T, ADCs, and bispecifics. 54 antibodies and research-grade proteins.

Antibodies • Biosimilars

TROP2 / Nectin-4

TACSTD2 / PVRL4

Emerging ADC targets for platinum-resistant ovarian cancer. 50+ combined antibodies and research-grade proteins.

Antibodies • Proteins • Biosimilars

WT1 / PAX8

Diagnostic Markers

WT1 and PAX8 IHC markers for serous ovarian cancer diagnosis and differentiation from other peritoneal malignancies.

Antibodies

Why Researchers Choose abinScience for Ovarian Cancer

CA125 + HE4 Dual BiomarkerAntibodies for both CA125/MUC16 and HE4/WFDC2, plus recombinant proteins for assay development.

ADC Target PortfolioFOLR1, Mesothelin, TROP2, Nectin-4 — antibodies and recombinant proteins for ADC target research.

Diagnostic IHC MarkersWT1, PAX8, and MUC1 antibodies for serous ovarian cancer diagnosis and differentiation in FFPE tissue panels.

Protein–Antibody–Kit WorkflowSame target as recombinant protein, detection antibody, and ELISA kit from one manufacturer for streamlined assay development.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

Serum biomarker ELISA development: Anti-CA125 and anti-HE4 antibodies and recombinant proteins available for assay development. Contact us for recommendations.
FOLR1-targeted ADC research: Anti-FOLR1 antibodies with FCM and IHC validation available. Research-grade FOLR1 biosimilar proteins with ELISA and FACS validation for comparability studies.
BRCA/HRD pathway studies: Use anti-BRCA1/2 and DNA repair pathway antibodies to characterize homologous recombination deficiency and PARP inhibitor sensitivity in ovarian cancer models.
Serous carcinoma differential diagnosis: Apply WT1, PAX8, and p53 antibodies in IHC panels to distinguish high-grade serous ovarian carcinoma from other histological subtypes.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What CA125 and HE4 reagents do you offer?

Anti-CA125/MUC16 monoclonal antibodies with FC validation (e.g., clones SAA0160, SAA0161, 3D5). Anti-HE4/WFDC2 antibodies and recombinant proteins also available. Contact us for pairing recommendations.

What FOLR1 reagents do you offer?

Anti-FOLR1 detection antibodies with FC and IHC validation. Research-grade biosimilar proteins (mirvetuximab, farletuzumab) with ELISA and FACS validation. Recombinant FOLR1 proteins (His/Fc-tagged) also available.

Do you carry Mesothelin reagents for CAR-T research?

Yes — anti-Mesothelin/MSLN antibodies and biosimilar proteins with ELISA and FACS validation. Recombinant MSLN proteins (His/Fc-tagged) also available.

What IHC panel differentiates serous from mucinous ovarian cancer?

We offer antibodies for WT1, PAX8, p53, and CK20. See product pages for validated applications and recommended IHC dilutions.

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.